University of Vermont

The University of Vermont Cancer Center

trials_lymph

Lymphoma Clinical Trials

The University of Vermont Cancer Center has many trials specifically focused on lymphoma research.

Status: Active - Recruiting
Study Title:
Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma
Purpose: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.
ClinicalTrials.gov Identifier: NCT00408005
Primary/Site/Co Investigator: Alan C Homans, MD
Contact: Alan Homans (802) 847-2850
Information: http://clinicaltrials.gov /ct2/show/NCT00408005?term=COG+AALL0434&rank=1
Institution Number: 00-327 COG AALL0434
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
COG AHOD04B1: Hodgkin Disease Banking Study
Purpose: This laboratory study is collecting and storing samples of tissue and blood from young patients with Hodgkin's lymphoma.
ClinicalTrials.gov Identifier: NCT00900250
Primary/Site/Co Investigator: Alan C Homans, MD
Contact: Alan Homans (802) 847-2850
Information: http://www.clinicaltrials.gov/ct2/show/NCT00900250?term=COG+AHOD04B1&rank=1
Institution Number: 00-327 COG AHOD04B1
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
CALGB 50801 - Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Purpose: To improve treatment outcomes in patients diagnosed with bulky, early stage Hodgkin lymphoma and to reduce the side effects that are associated with use of radiation used in current treatments.
ClinicalTrials.gov Identifier: NCT01118026
Primary/Site/Co Investigator: Julian Sprague, MD, PhD
Contact: Jane Walsh (802) 656-9926
Information: http://www.clinicaltrials.gov/ct2/show/NCT01118026?term=CALGB+50801&rank=1
Institution Number: M11-159
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
Janssen PCI-32765FLR2002: An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (ibrutinib) in Subjects with Refractory Follicular Lymphoma
Purpose: The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).
ClinicalTrials.gov Identifier: NCT01779791
Primary/Site/Co Investigator: Julian Sprague, MD
Contact: Sam Cory (802) 656-9446
Information: http://clinicaltrials.gov/ct2/show/NCT01779791?term=flr2002&rank=1
Institution Number: 13-155
Protocol Research Type: Industry
Status: Active - Recruiting
Study Title:
Millennium C14012: A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Purpose: This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or romidepsin, in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Note: romidepsin will not be used as a single-agent comparator in countries that do not permit its use at this time.
ClinicalTrials.gov Identifier: NCT01482962
Primary/Site/Co Investigator: Julian Sprague, MD, PhD
Contact: Sam Cory (802) 656-9446
Information: http://clinicaltrials.gov/ct2/show/NCT01482962?term=C14012&rank=1
Institution Number: 12-240
Protocol Research Type: Industry
Status: Active - Recruiting
Study Title: Janssen PCI-32765MCL3002 - A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
Purpose: The purpose of this study is to compare the effects (both good and bad) of Ibrutinib when it is given with Bendamustine (known as Treanda) and Rituximab (known as Rituxan) to Bendamustine and Rituximab alone.
ClinicalTrials.gov Identifier: NCT01776840
Primary/Site/Co Investigator:
Contact: Karen Lepuschenko (802) 656-9924
Information: http://clinicaltrials.gov/ct2/show/NCT001776840NCT001776840
Institution Number: M13-223
Protocol Research Type: Industry
Status: Active - Recruiting
Study Title: Janssen PCI-32765DBL3001 - A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Purpose: The purpose of this study is to compare the effects (both good and bad) of ibrutinib when it is given in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (abbreviated as R-CHOP) to R-CHOP and placebo.  R-CHOP is the standard treatment already used to treat Diffuse Large B-Cell Lymphoma. 
ClinicalTrials.gov Identifier: NCT01855750
Primary/Site/Co Investigator: Julian Sprague, PhD
Contact: Karen Lepuschenko (802) 656-9924
Information:
Institution Number: M14-015
Protocol Research Type: Industry
Status: Active - Closed to Accrual
Study Title:
Janssen PCI-32765MCL4001: An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Purpose: The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.
ClinicalTrials.gov Identifier: NCT01833039
Primary/Site/Co Investigator: Julian Sprague, MD
Contact: Sam Cory (802) 656-9446
Information: http://clinicaltrials.gov/ct2/show/study/NCT01833039?term=mcl4001&rank=1&show_locs=Y#locn
Institution Number: 13-264
Protocol Research Type: Industry
Status: Active - Closed to Accrual
Study Title: CALGB 50604: Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma
Purpose: To try and improve treatment outcomes and delayed side effects in untreated patients diagnosed with early stage Hodgkin lymphoma.
ClinicalTrials.gov Identifier: NCT01132807
Primary/Site/Co Investigator: Julian Sprague, MD, PhD
Contact: Jane Walsh (802) 656-9926
Information: http://clinicaltrials.gov/ct2/show/NCT01132807?term=CALBG50604&rank=1
Institution Number: M11-154
Protocol Research Type: Cooperative Group
Status: Active - Closed to Accrual
Study Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus Matching Placebo After Patients Have Achieved Complete Response with First-Line Rituximab-Chemotherapy
Purpose: Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy
ClinicalTrials.gov Identifier: NCT00790036
Primary/Site/Co Investigator: Julian Sprague, MD, PhD
Contact: Karen Lepuschenko (802) 656-9924
Information: http://www.clinicaltrials.gov/ct2/show/NCT00790036?term=Phase+III+Study+of+RAD001&rank=1
Institution Number: M10-042
Protocol Research Type: Industry

 

Last modified December 08 2014 12:09 PM